Selank for Anxiety: The Non-Addictive Peptide Alternative to Benzodiazepines
For millions suffering from generalised anxiety disorder (GAD) and stress-related conditions, the search for effective treatment often leads to a difficult choice between symptom relief and unwanted side effects.
Traditional benzodiazepines work, but they carry significant risks of sedation, cognitive impairment, and dependency. Selank, a synthetic peptide developed in Russia, offers a potential alternative that may provide comparable anxiety relief without these drawbacks.
What Is Selank?
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from tuftsin, an endogenous immunomodulatory peptide. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in collaboration with the Zakusov Research Institute of Pharmacology. The compound has been studied for its anxiolytic and nootropic properties, positioning it as a potential therapeutic agent for both anxiety and cognitive disorders.
Unlike benzodiazepines, which are well-established in international medical practice, Selank is currently approved only in Russia and Belarus, where it is available as 0.15% nasal drops for the treatment of generalised anxiety disorder and neurasthenia.
How Selank Works: Mechanisms of Action
Selank's mechanism is multifaceted, distinguishing it from the single-target approach of benzodiazepines.
GABAergic System Modulation
A primary mechanism underlying Selank's anxiolytic effects is its interaction with the GABAergic system, the brain's main inhibitory neurotransmitter pathway. Selank acts as a positive allosteric modulator of GABA-A receptors, enhancing the binding of the neurotransmitter GABA and increasing chloride ion influx. This results in reduced neuronal excitability and a calming effect.
Importantly, Selank's binding site on the receptor appears to be distinct from that of benzodiazepines. This may explain why Selank can produce anxiolysis without the sedation and cognitive impairment associated with traditional benzodiazepines.
Monoamine System Regulation
Selank influences multiple neurotransmitter systems beyond GABA. Animal studies have shown that it can affect serotonin and dopamine levels in various brain regions, with effects depending on the baseline state of the neurochemical systems and mouse strain. In rats subjected to antenatal hypoxia, Selank restored balance between serotoninergic and noradrenergic systems.
Brain-Derived Neurotrophic Factor (BDNF) Upregulation
One of Selank's most promising mechanisms is its ability to rapidly increase the expression of BDNF in the hippocampus. BDNF is critical for neuronal survival, synaptic plasticity, learning, and memory. This mechanism likely underpins Selank's nootropic (cognitive-enhancing) properties.
Enkephalinase Inhibition and Immunomodulation
Selank inhibits enzymes responsible for degrading enkephalins—endogenous opioid peptides with anxiolytic properties—with an IC50 of 15 µM for plasma enkephalin hydrolysis. It also modulates cytokine expression, including suppression of the pro-inflammatory interleukin-6 (IL-6) gene in patients with anxiety-asthenic disorders. This immunomodulatory activity stems from Selank's structural heritage as a tuftsin analogue.
Clinical Evidence: Efficacy and Comparison to Benzodiazepines
Selank vs. Medazepam
A clinical trial enrolled 62 patients with generalised anxiety disorder and neurasthenia (30 receiving Selank, 32 receiving medazepam, a benzodiazepine). Outcomes were measured using Hamilton, Zung, and Clinical Global Impression scales, plus serum enkephalin activity. Selank produced anxiolytic activity characterised as similar to medazepam on all scales, with two notable additions: antiasthenic (anti-fatigue) effects and a psychostimulant effect not seen with the benzodiazepine. Selank treatment also increased serum enkephalin half-life, correlating with anxiety reduction.
Selank vs. Phenazepam
A 2014 trial in 60 patients with phobic-anxiety and somatoform disorders compared Selank to phenazepam, a high-potency Russian benzodiazepine. Selank demonstrated pronounced anxiolytic effects and mild nootropic effects. Critically, the anxiolytic effect persisted for approximately one week after the last dose. A follow-up 2015 study involving 70 patients examined combining Selank with phenazepam, reporting faster onset of symptom improvement on the Hamilton Depression Rating Scale (HDRS) and reduced incidence of phenazepam-related side effects, including attention and memory impairment, sedation, increased sleep duration, and sexual dysfunction.
Post-COVID Asthenia
A 2024 study investigated Selank in 64 patients with post-COVID asthenia and decreased performance. Patients receiving Selank (nasal drops, 1.5 mg, 2-3 drops four times daily for 30 days) alongside a neuroprotective complex showed good symptom relief, with concurrent improvement in anxiety and depressive symptoms.
Comparative Safety and Tolerability
The Benzodiazepine Problem
Benzodiazepines bind to a specific allosteric site on the GABA-A receptor, potentiating GABA's effects. This mechanism explains both their therapeutic benefits and their well-documented drawbacks: sedation, myorelaxation, cognitive impairment, tolerance, dependence, and withdrawal syndrome. Long-term use is particularly problematic, with tolerance to anxiolytic effects developing in as little as six days in animal models.
Selank's Safety Profile
Selank appears to offer a more favourable safety profile. Available data suggests it produces anxiolytic effects without the significant sedative, cognitive, and addictive properties of benzodiazepines. Documented side effects are mild, primarily limited to nasal mucosa irritation and rare allergic reactions. No serious adverse events have been reported in available studies.
Evidence Limitations and Regulatory Status
Critical methodological caution is warranted when evaluating Selank's evidence base. The trials are small by Western RCT standards, conducted at single Russian sites, and have not been reproduced by independent research groups outside Russia. The clinical trial designs used medazepam and phenazepam as comparators, not a placebo, limiting conclusions about absolute efficacy. No Phase 3 trials using CONSORT-compliant methodology with pre-registered endpoints have been published in any Western journal.
As of April 2026, Selank is classified as an FDA Category 2 bulk drug substance under Section 503A of the Federal Food, Drug, and Cosmetic Act, meaning the FDA is still evaluating whether Selank is appropriate for compounding. It has no FDA-approved indication for any use in the United States. The absence of Western replication is not evidence that the Russian findings are wrong, but it is a meaningful gap in the evidence base.
Practical Considerations
Sources and Quality Risks
Selank products sold through online vendors without a prescription are not regulated by the FDA. Independent testing of research peptides has documented issues including incorrect concentrations, contamination, and misidentified compounds. FDA warning letters to online peptide suppliers have cited precisely these product quality failures. For those in jurisdictions where licensed compounding pharmacies can provide Selank with a valid prescription, quality control is more consistent.
Contraindications
Selank is contraindicated during pregnancy and breastfeeding and is not recommended for individuals under age 18. Drug interactions require careful review, especially with other serotonergic medications.
Conclusion
Selank represents an intriguing research compound with a mechanism of action distinct from traditional benzodiazepines. Its multifaceted approach—GABA-A receptor modulation, monoamine regulation, BDNF upregulation, enkephalinase inhibition, and immunomodulation—may explain its reported anxiolytic efficacy without the common drawbacks of sedation, cognitive impairment, and dependence.
However, the evidence base is limited to small Russian trials that have not been independently replicated in the West. Regulatory status outside Russia remains investigational, and quality control for non-prescription sources is a significant concern. For researchers and clinicians exploring alternatives to benzodiazepines, Selank merits further investigation. For individuals seeking anxiety relief, consultation with a qualified healthcare provider is essential, as Selank is not an FDA-approved treatment and should not replace therapies with proven benefit.
Comments
Post a Comment